Regulation of TCR signalling by tyrosine phosphatases: From immune homeostasis to autoimmunity

Immunology

Volumn 137, Issue 1, 2012, Pages 1-19

  Stanford, Stephanie M ^a   Rapini, Novella ^a   Bottini, Nunzio ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

Autoimmunity; Protein tyrosine phosphatase; T cell activation; T cell receptor signalling; Tyrosine phosphorylation

Indexed keywords

CD45 ANTIGEN; IMMUNOMODULATING AGENT; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE; STAT5 PROTEIN; T LYMPHOCYTE RECEPTOR;

APOPTOSIS; AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; AUTOIMMUNITY; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL LINE; ENZYME ACTIVITY; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; HOMEOSTASIS; HUMAN; IMMUNOMODULATION; INTRACELLULAR SIGNALING; MULTIPLE SCLEROSIS; MYASTHENIA; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; REVIEW; SEVERE COMBINED IMMUNODEFICIENCY; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; T LYMPHOCYTE ACTIVATION; THYMOCYTE; TRANSCRIPTION REGULATION;

ANIMALS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; CELL COMMUNICATION; HOMEOSTASIS; HUMANS; LYMPHOCYTE ACTIVATION; MICE; PROTEIN TYROSINE PHOSPHATASES; RECEPTORS, ANTIGEN, T-CELL; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 84864762292     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2012.03591.x     Document Type: Review

References (290)

1. van der Merwe PA, Dushek O. Mechanisms for T cell receptor triggering. Nat Rev 2011; 11:47-55.
2. Smith-Garvin JE, Koretzky GA, Jordan MS. T cell activation. Annu Rev Immunol 2009; 27:591-619.
3. Acuto O, Di Bartolo V, Michel F. Tailoring T-cell receptor signals by proximal negative feedback mechanisms. Nat Rev 2008; 8:699-712.
4. Weiss A. The right team at the right time to go for a home run: tyrosine kinase activation by the TCR. Nat Immunol 2010; 11:101-4.
5. Davis SJ, van der Merwe PA. The kinetic-segregation model: TCR triggering and beyond. Nat Immunol 2006; 7:803-9.
6. Alonso A, Sasin J, Bottini N et al. Protein tyrosine phosphatases in the human genome. Cell 2004; 117:699-711.
7. Andersen JN, Jansen PG, Echwald SM, Mortensen OH, Fukada T, Del Vecchio R, Tonks NK, Moller NP. A genomic perspective on protein tyrosine phosphatases: gene structure, pseudogenes, and genetic disease linkage. FASEB J 2004; 18:8-30.
8. Mustelin T, Vang T, Bottini N. Protein tyrosine phosphatases and the immune response. Nat Rev Immunol 2005; 5:43-57.
9. Arimura Y, Yagi J. Comprehensive expression profiles of genes for protein tyrosine phosphatases in immune cells. Sci Signal 2010; 3:rs1.
10. Zikherman J, Weiss A. Antigen receptor signaling in the rheumatic diseases. Arthritis Res Ther 2009; 11:202.
11. Sakaguchi S, Tanaka S, Tanaka A, Ito Y, Maeda S, Sakaguchi N, Hashimoto M. Thymus, innate immunity and autoimmune arthritis: interplay of gene and environment. FEBS Lett 2011; 585:3633-9.
12. Gregersen PK, Behrens TW. Genetics of autoimmune diseases - disorders of immune homeostasis. Nat Rev Genet 2006; 7:917-28.
13. Thomas ML. The leukocyte common antigen family. Annu Rev Immunol 1989; 7:339-69.
14. Desai DM, Sap J, Silvennoinen O, Schlessinger J, Weiss A. The catalytic activity of the CD45 membrane-proximal phosphatase domain is required for TCR signaling and regulation. EMBO J 1994; 13:4002-10.
15. Hermiston ML, Xu Z, Weiss A. CD45: a critical regulator of signaling thresholds in immune cells. Annu Rev Immunol 2003; 21:107-37.
16. Saunders AE, Johnson P. Modulation of immune cell signalling by the leukocyte common tyrosine phosphatase, CD45. Cell Signal 2010; 22:339-48.
17. Irie-Sasaki J, Sasaki T, Penninger JM. CD45 regulated signaling pathways. Curr Top Med Chem 2003; 3:783-96.
18. Ostergaard HL, Shackelford DA, Hurley TR, Johnson P, Hyman R, Sefton BM, Trowbridge IS. Expression of CD45 alters phosphorylation of the lck-encoded tyrosine protein kinase in murine lymphoma T-cell lines. Proc Natl Acad Sci U S A 1989; 86:8959-63.
19. Mustelin T, Coggeshall KM, Altman A. Rapid activation of the T-cell tyrosine protein kinase pp56lck by the CD45 phosphotyrosine phosphatase. Proc Natl Acad Sci U S A 1989; 86:6302-6.
20. Mustelin T, Pessa-Morikawa T, Autero M, Gassmann M, Andersson LC, Gahmberg CG, Burn P. Regulation of the p59fyn protein tyrosine kinase by the CD45 phosphotyrosine phosphatase. Eur J Immunol 1992; 22:1173-8.
21. Hurley TR, Hyman R, Sefton BM. Differential effects of expression of the CD45 tyrosine protein phosphatase on the tyrosine phosphorylation of the lck, fyn, and c-src tyrosine protein kinases. Mol Cell Biol 1993; 13:1651-6.
22. Seavitt JR, White LS, Murphy KM, Loh DY, Perlmutter RM, Thomas ML. Expression of the p56(Lck) Y505F mutation in CD45-deficient mice rescues thymocyte development. Mol Cell Biol 1999; 19:4200-8.
23. Pingel S, Baker M, Turner M, Holmes N, Alexander DR. The CD45 tyrosine phosphatase regulates CD3-induced signal transduction and T cell development in recombinase-deficient mice: restoration of pre-TCR function by active p56(lck). Eur J Immunol 1999; 29:2376-84.
24. Cahir McFarland ED, Hurley TR, Pingel JT, Sefton BM, Shaw A, Thomas ML. Correlation between Src family member regulation by the protein-tyrosine-phosphatase CD45 and transmembrane signaling through the T-cell receptor. Proc Natl Acad Sci U S A 1993; 90:1402-6.
25. Shiroo M, Goff L, Biffen M, Shivnan E, Alexander D. CD45 tyrosine phosphatase-activated p59fyn couples the T cell antigen receptor to pathways of diacylglycerol production, protein kinase C activation and calcium influx. EMBO J 1992; 11:4887-97.
26. Stone JD, Conroy LA, Byth KF, Hederer RA, Howlett S, Takemoto Y, Holmes N, Alexander DR. Aberrant TCR-mediated signaling in CD45-null thymocytes involves dysfunctional regulation of Lck, Fyn, TCR-ξ, and ZAP-70. J Immunol 1997; 158:5773-82.
27. D'Oro U, Ashwell JD. Cutting edge: the CD45 tyrosine phosphatase is an inhibitor of Lck activity in thymocytes. J Immunol 1999; 162:1879-83.
28. Burns CM, Sakaguchi K, Appella E, Ashwell JD. CD45 regulation of tyrosine phosphorylation and enzyme activity of src family kinases. J Biol Chem 1994; 269:13594-600.
29. D'Oro U, Sakaguchi K, Appella E, Ashwell JD. Mutational analysis of Lck in CD45-negative T cells: dominant role of tyrosine 394 phosphorylation in kinase activity. Mol Cell Biol 1996; 16:4996-5003.
30. Baker M, Gamble J, Tooze R et al. Development of T-leukaemias in CD45 tyrosine phosphatase-deficient mutant lck mice. EMBO J 2000; 19:4644-54.
31. Kung C, Pingel JT, Heikinheimo M et al. Mutations in the tyrosine phosphatase CD45 gene in a child with severe combined immunodeficiency disease. Nat Med 2000; 6:343-5.
32. Tchilian EZ, Wallace DL, Wells RS, Flower DR, Morgan G, Beverley PC. A deletion in the gene encoding the CD45 antigen in a patient with SCID. J Immunol 2001; 166:1308-13.
33. Kishihara K, Penninger J, Wallace VA et al. Normal B lymphocyte development but impaired T cell maturation in CD45-exon6 protein tyrosine phosphatase-deficient mice. Cell 1993; 74:143-56.
34. Mee PJ, Turner M, Basson MA, Costello PS, Zamoyska R, Tybulewicz VL. Greatly reduced efficiency of both positive and negative selection of thymocytes in CD45 tyrosine phosphatase-deficient mice. Eur J Immunol 1999; 29:2923-33.
35. + thymocytes, and B cell maturation. J Exp Med 1996; 183:1707-18.
36. McNeill L, Salmond RJ, Cooper JC et al. The differential regulation of Lck kinase phosphorylation sites by CD45 is critical for T cell receptor signaling responses. Immunity 2007; 27:425-37.
37. Zikherman J, Jenne C, Watson S, Doan K, Raschke W, Goodnow CC, Weiss A. CD45-Csk phosphatase-kinase titration uncouples basal and inducible T cell receptor signaling during thymic development. Immunity 2010; 32:342-54.
38. Trowbridge IS, Thomas ML. CD45: an emerging role as a protein tyrosine phosphatase required for lymphocyte activation and development. Annu Rev Immunol 1994; 12:85-116.
39. Vang T, Miletic AV, Arimura Y, Tautz L, Rickert RC, Mustelin T. Protein tyrosine phosphatases in autoimmunity. Annu Rev Immunol 2008; 26:29-55.
40. Wu Z, Jia X, de la Cruz L et al. Memory T cell RNA rearrangement programmed by heterogeneous nuclear ribonucleoprotein hnRNPLL. Immunity 2008; 29:863-75.
41. Oberdoerffer S, Moita LF, Neems D, Freitas RP, Hacohen N, Rao A. Regulation of CD45 alternative splicing by heterogeneous ribonucleoprotein, hnRNPLL. Science (New York, NY 2008; 321:686-91.
42. Topp JD, Jackson J, Melton AA, Lynch KW. A cell-based screen for splicing regulators identifies hnRNP LL as a distinct signal-induced repressor of CD45 variable exon 4. RNA 2008; 14:2038-49.
43. Kozieradzki I, Kundig T, Kishihara K et al. T cell development in mice expressing splice variants of the protein tyrosine phosphatase CD45. J Immunol 1997; 158:3130-9.
44. Ogilvy S, Louis-Dit-Sully C, Cooper J, Cassady RL, Alexander DR, Holmes N. Either of the CD45RB and CD45RO isoforms are effective in restoring T cell, but not B cell, development and function in CD45-null mice. J Immunol 2003; 171:1792-800.
45. + T cell hyper-responsiveness in CD45 transgenic mice is independent of isoform. Int Immunol 2008; 20:819-27.
46. Novak TJ, Farber D, Leitenberg D, Hong SC, Johnson P, Bottomly K. Isoforms of the transmembrane tyrosine phosphatase CD45 differentially affect T cell recognition. Immunity 1994; 1:109-19.
47. Tchilian EZ, Dawes R, Hyland L et al. Altered CD45 isoform expression affects lymphocyte function in CD45 Tg mice. Int Immunol 2004; 16:1323-32.
48. Dawes R, Petrova S, Liu Z, Wraith D, Beverley PC, Tchilian EZ. Combinations of CD45 isoforms are crucial for immune function and disease. J Immunol 2006; 176:3417-25.
49. + T cells. Immunol Lett 2010; 129:39-46.
50. Majeti R, Xu Z, Parslow TG, Olson JL, Daikh DI, Killeen N, Weiss A. An inactivating point mutation in the inhibitory wedge of CD45 causes lymphoproliferation and autoimmunity. Cell 2000; 103:1059-70.
51. Hermiston ML, Zikherman J, Tan AL et al. Differential impact of the CD45 juxtamembrane wedge on central and peripheral T cell receptor responses. Proc Natl Acad Sci U S A 2009; 106:546-51.
52. Takeuchi T, Pang M, Amano K, Koide J, Abe T. Reduced protein tyrosine phosphatase (PTPase) activity of CD45 on peripheral blood lymphocytes in patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 1997; 109:20-6.
53. Blasini AM, Alonzo E, Chacon R, Riera R, Stekman IL, Rodriguez MA. Abnormal pattern of tyrosine phosphorylation in unstimulated peripheral blood T lymphocytes from patients with systemic lupus erythematosus. Lupus 1998; 7:515-23.
54. + peripheral blood T-lymphocytes is related to auto-immune processes and hematological manifestations in systemic lupus erythematosus. Schweiz Med Wochenschr 1996; 126:1922-5.
55. + T lymphocytes in children with infantile cholestasis. Immunol Lett 2001; 75:179-84.
56. Thude H, Hundrieser J, Wonigeit K, Schwinzer R. A point mutation in the human CD45 gene associated with defective splicing of exon A. Eur J Immunol 1995; 25:2101-6.
57. Lynch KW, Weiss A. A CD45 polymorphism associated with multiple sclerosis disrupts an exonic splicing silencer. J Biol Chem 2001; 276:24341-7.
58. Jacobsen M, Schweer D, Ziegler A et al. A point mutation in PTPRC is associated with the development of multiple sclerosis. Nat Genet 2000; 26:495-9.
59. Barcellos LF, Caillier S, Dragone L et al. PTPRC (CD45) is not associated with the development of multiple sclerosis in U.S. patients. Nat Genet 2001; 29:23-4.
60. Vorechovsky I, Kralovicova J, Tchilian E et al. Does 77C→G in PTPRC modify autoimmune disorders linked to the major histocompatibility locus?Nat Genet 2001; 29:22-3.
61. Gomez-Lira M, Liguori M, Magnani C et al. CD45 and multiple sclerosis: the exon 4 C77G polymorphism (additional studies and meta-analysis) and new markers. J Neuroimmunol 2003; 140:216-21.
62. Szvetko AL, Jones A, Mackenzie J, Tajouri L, Csurhes PA, Greer JM, Pender MP, Griffiths LR. An investigation of the C77G and C772T variations within the human protein tyrosine phosphatase receptor type C gene for association with multiple sclerosis in an Australian population. Brain Res 2009; 1255:148-52.
63. Wood JP, Bieda K, Segni M, Herwig J, Krause M, Usadel KH, Badenhoop K. CD45 exon 4 point mutation does not confer susceptibility to type 1 diabetes mellitus or Graves' disease. Eur J Immunogenet 2002; 29:73-4.
64. Thude H, Rosenhahn S, Hunger-Dathe W, Muller UA, Barz D. A transmembrane protein-tyrosine phosphatase receptor type C (CD45) exon A point mutation (77 C to G) is not associated with the development of type 1 diabetes mellitus in a German population. Eur J Immunogenet 2004; 31:245-7.
65. Johanneson B, Lima G, von Salome J, Alarcon-Segovia D, Alarcon-Riquelme ME. A major susceptibility locus for systemic lupus erythemathosus maps to chromosome 1q31. Am J Hum Genet 2002; 71:1060-71.
66. Thude H, Weissenborn S, Vilser C, Muller UA, Kloos C, Wolf G, Beck J, Barz D. No association between transmembrane protein-tyrosine-phosphatase receptor type C (CD45) exon A 77C>G transversion and Hashimoto's thyroiditis in a German population. Hum Immunol 2010; 71:220-3.
67. Ramanujam R, Pirskanen R, Hammarstrom L. The CD45 77C/G allele is not associated with myasthenia gravis - a reassessment of the potential role of CD45 in autoimmunity. BMC Res Notes 2010; 3:292.
68. Vogel A, Strassburg CP, Manns MP. 77 C/G mutation in the tyrosine phosphatase CD45 gene and autoimmune hepatitis: evidence for a genetic link. Genes Immun 2003; 4:79-81.
69. Schwinzer R, Witte T, Hundrieser J et al. Enhanced frequency of a PTPRC (CD45) exon A mutation (77C>G) in systemic sclerosis. Genes Immun 2003; 4:168-9.
70. Gaya A, Pirotto F, Palou E, Autschbach F, Del Pozo V, Sole J, Serra-Pages C. CD148, a new membrane tyrosine phosphatase involved in leukocyte function. Leuk Lymphoma 1999; 35:237-43.
71. Hermiston ML, Zikherman J, Zhu JW. CD45, CD148, and Lyp/Pep: critical phosphatases regulating Src family kinase signaling networks in immune cells. Immunol Rev 2009; 228:288-311.
72. Lin J, Zhu JW, Baker JE, Weiss A. Regulated expression of the receptor-like tyrosine phosphatase CD148 on hemopoietic cells. J Immunol 2004; 173:2324-30.
73. Autschbach F, Palou E, Mechtersheimer G et al. Expression of the membrane protein tyrosine phosphatase CD148 in human tissues. Tissue Antigens 1999; 54:485-98.
74. Tangye SG, Phillips JH, Lanier LL, de Vries JE, Aversa G. CD148: a receptor-type protein tyrosine phosphatase involved in the regulation of human T cell activation. J Immunol 1998; 161:3249-55.
75. Stepanek O, Kalina T, Draber P et al. Regulation of Src family kinases involved in T cell receptor signaling by protein-tyrosine phosphatase CD148. J Biol Chem 2011; 286:22101-12.
76. Baker JE, Majeti R, Tangye SG, Weiss A. Protein tyrosine phosphatase CD148-mediated inhibition of T-cell receptor signal transduction is associated with reduced LAT and phospholipase Cγ1 phosphorylation. Mol Cell Biol 2001; 21:2393-403.
77. Lin J, Weiss A. The tyrosine phosphatase CD148 is excluded from the immunologic synapse and down-regulates prolonged T cell signaling. J Cell Biol 2003; 162:673-82.
78. Sap J, D'Eustachio P, Givol D, Schlessinger J. Cloning and expression of a widely expressed receptor tyrosine phosphatase. Proc Natl Acad Sci U S A 1990; 87:6112-6.
79. Su J, Muranjan M, Sap J. Receptor protein tyrosine phosphatase alpha activates Src-family kinases and controls integrin-mediated responses in fibroblasts. Curr Biol 1999; 9:505-11.
80. Ng DH, Jabali MD, Maiti A et al. CD45 and RPTPalpha display different protein tyrosine phosphatase activities in T lymphocytes. Biochem J 1997; 327(Pt 3):867-76.
81. Maksumova L, Le HT, Muratkhodjaev F, Davidson D, Veillette A, Pallen CJ. Protein tyrosine phosphatase alpha regulates Fyn activity and Cbp/PAG phosphorylation in thymocyte lipid rafts. J Immunol 2005; 175:7947-56.
82. Yang Y, Gil M, Byun SM, Choi I, Pyun KH, Ha H. Transforming growth factor-β1 inhibits human keratinocyte proliferation by upregulation of a receptor-type tyrosine phosphatase R-PTP-κ gene expression. Biochem Biophys Res Commun 1996; 228:807-12.
83. Wang SE, Wu FY, Shin I, Qu S, Arteaga CL. Transforming growth factor β (TGF-β)-Smad target gene protein tyrosine phosphatase receptor type κ is required for TGF-β function. Mol Cell Biol 2005; 25:4703-15.
84. Asano A, Tsubomatsu K, Jung CG, Sasaki N, Agui T. A deletion mutation of the protein tyrosine phosphatase κ (Ptprk) gene is responsible for T-helper immunodeficiency (thid) in the LEC rat. Mamm Genome 2007; 18:779-86.
85. Kose H, Sakai T, Tsukumo S, Wei K, Yamada T, Yasutomo K, Matsumoto K. Maturational arrest of thymocyte development is caused by a deletion in the receptor-like protein tyrosine phosphatase κ gene in LEC rats. Genomics 2007; 89:673-7.
86. - thymocytes in a mutant strain (LEC) of rat. J Exp Med 1990; 172:1615-24.
87. Iwata R, Sasaki N, Agui T. Contiguous gene deletion of Ptprk and Themis causes T-helper immunodeficiency (thid) in the LEC rat. Biomed Res 2010; 31:83-7.
88. + T cell development through ERK1/2-mediated signaling. Biochem Biophys Res Commun 2009; 390:489-93.
89. Tsujikawa K, Ichijo T, Moriyama K et al. Regulation of Lck and Fyn tyrosine kinase activities by transmembrane protein tyrosine phosphatase leukocyte common antigen-related molecule. Mol Cancer Res 2002; 1:155-63.
90. Kondo S, Kishi H, Muraguchi A. Regulatory role of leukocyte-common-antigen-related molecule (LAR) in thymocyte differentiation. Eur J Immunol 2010; 40:1296-302.
91. Cohen S, Dadi H, Shaoul E, Sharfe N, Roifman CM. Cloning and characterization of a lymphoid-specific, inducible human protein tyrosine phosphatase, Lyp. Blood 1999; 93:2013-24.
92. Matthews RJ, Bowne DB, Flores E, Thomas ML. Characterization of hematopoietic intracellular protein tyrosine phosphatases: description of a phosphatase containing an SH2 domain and another enriched in proline-, glutamic acid-, serine-, and threonine-rich sequences. Mol Cell Biol 1992; 12:2396-405.
93. Veillette A, Rhee I, Souza CM, Davidson D. PEST family phosphatases in immunity, autoimmunity, and autoinflammatory disorders. Immunol Rev 2009; 228:312-24.
94. Cloutier JF, Veillette A. Association of inhibitory tyrosine protein kinase p50csk with protein tyrosine phosphatase PEP in T cells and other hemopoietic cells. EMBO J 1996; 15:4909-18.
95. Cloutier JF, Veillette A. Cooperative inhibition of T-cell antigen receptor signaling by a complex between a kinase and a phosphatase. J Exp Med 1999; 189:111-21.
96. Gjorloff-Wingren A, Saxena M, Williams S, Hammi D, Mustelin T. Characterization of TCR-induced receptor-proximal signaling events negatively regulated by the protein tyrosine phosphatase PEP. Eur J Immunol 1999; 29:3845-54.
97. Wu J, Katrekar A, Honigberg LA et al. Identification of substrates of human protein-tyrosine phosphatase PTPN22. J Biol Chem 2006; 281:11002-10.
98. Hill RJ, Zozulya S, Lu YL, Ward K, Gishizky M, Jallal B. The lymphoid protein tyrosine phosphatase Lyp interacts with the adaptor molecule Grb2 and functions as a negative regulator of T-cell activation. Exp Hematol 2002; 30:237-44.
99. Begovich AB, Carlton VE, Honigberg LA et al. A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am J Hum Genet 2004; 75:330-7.
100. Vang T, Congia M, Macis MD et al. Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nat Genet 2005; 37:1317-9.
101. Yu X, Sun JP, He Y, Guo X, Liu S, Zhou B, Hudmon A, Zhang ZY. Structure, inhibitor, and regulatory mechanism of Lyp, a lymphoid-specific tyrosine phosphatase implicated in autoimmune diseases. Proc Natl Acad Sci U S A 2007; 104:19767-72.
102. Orru V, Tsai SJ, Rueda B et al. A loss-of-function variant of PTPN22 is associated with reduced risk of systemic lupus erythematosus. Hum Mol Genet 2009; 18:569-79.
103. Fiorillo E, Orru V, Stanford SM et al. Autoimmune-associated PTPN22 R620W variation reduces phosphorylation of lymphoid phosphatase on an inhibitory tyrosine residue. J Biol Chem 2010; 285:26506-18.
104. Hasegawa K, Martin F, Huang G, Tumas D, Diehl L, Chan AC. PEST domain-enriched tyrosine phosphatase (PEP) regulation of effector/memory T cells. Science (New York, NY 2004; 303:685-9.
105. Bottini N, Musumeci L, Alonso A et al. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat Genet 2004; 36:337-8.
106. Gregorieff A, Cloutier JF, Veillette A. Sequence requirements for association of protein-tyrosine phosphatase PEP with the Src homology 3 domain of inhibitory tyrosine protein kinase p50(csk). J Biol Chem 1998; 273:13217-22.
107. Ghose R, Shekhtman A, Goger MJ, Ji H, Cowburn D. A novel, specific interaction involving the Csk SH3 domain and its natural ligand. Nat Struct Biol 2001; 8:998-1004.
108. Tsai SJ, Sen U, Zhao L et al. Crystal structure of the human lymphoid tyrosine phosphatase catalytic domain: insights into redox regulation. Biochemistry 2009; 48:4838-45.
109. Liu Y, Stanford SM, Jog SP, Fiorillo E, Orru V, Comai L, Bottini N. Regulation of lymphoid tyrosine phosphatase activity: inhibition of the catalytic domain by the proximal interdomain. Biochemistry 2009; 48:7525-32.
110. Kyogoku C, Langefeld CD, Ortmann WA et al. Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE. Am J Hum Genet 2004; 75:504-7.
111. Stanford SM, Mustelin TM, Bottini N. Lymphoid tyrosine phosphatase and autoimmunity: human genetics rediscovers tyrosine phosphatases. Semin Immunopathol 2010; 32:127-36.
112. Viken MK, Amundsen SS, Kvien TK et al. Association analysis of the 1858C>T polymorphism in the PTPN22 gene in juvenile idiopathic arthritis and other autoimmune diseases. Genes Immun 2005; 6:271-3.
113. Hinks A, Barton A, John S et al. Association between the PTPN22 gene and rheumatoid arthritis and juvenile idiopathic arthritis in a UK population: further support that PTPN22 is an autoimmunity gene. Arthritis Rheum 2005; 52:1694-9.
114. Smyth D, Cooper JD, Collins JE et al. Replication of an association between the lymphoid tyrosine phosphatase locus (LYP/PTPN22) with type 1 diabetes, and evidence for its role as a general autoimmunity locus. Diabetes 2004; 53:3020-3.
115. Velaga MR, Wilson V, Jennings CE et al. The codon 620 tryptophan allele of the lymphoid tyrosine phosphatase (LYP) gene is a major determinant of Graves' disease. J Clin Endocrinol Metab 2004; 89:5862-5.
116. Skorka A, Bednarczuk T, Bar-Andziak E, Nauman J, Ploski R. Lymphoid tyrosine phosphatase (PTPN22/LYP) variant and Graves' disease in a Polish population: association and gene dose-dependent correlation with age of onset. Clin Endocrinol 2005; 62:679-82.
117. Heward JM, Brand OJ, Barrett JC, Carr-Smith JD, Franklyn JA, Gough SC. Association of PTPN22 haplotypes with Graves' disease. J Clin Endocrinol Metab 2007; 92:685-90.
118. Criswell LA, Pfeiffer KA, Lum RF et al. Analysis of families in the multiple autoimmune disease genetics consortium (MADGC) collection: the PTPN22 620W allele associates with multiple autoimmune phenotypes. Am J Hum Genet 2005; 76:561-71.
119. Skinningsrud B, Husebye ES, Gervin K et al. Mutation screening of PTPN22: association of the 1858T-allele with Addison's disease. Eur J Hum Genet 2008; 16:977-82.
120. Vandiedonck C, Capdevielle C, Giraud M et al. Association of the PTPN22*R620W polymorphism with autoimmune myasthenia gravis. Ann Neurol 2006; 59:404-7.
121. Greve B, Hoffmann P, Illes Z, Rozsa C, Berger K, Weissert R, Melms A. The autoimmunity-related polymorphism PTPN22 1858C/T is associated with anti-titin antibody-positive myasthenia gravis. Hum Immunol 2009; 70:540-2.
122. Chuang WY, Strobel P, Belharazem D et al. The PTPN22(gain-of-function)+1858T(+) genotypes correlate with low IL-2 expression in thymomas and predispose to myasthenia gravis. Genes Immun 2009; 10:667-72.
123. Canton I, Akhtar S, Gavalas NG, Gawkrodger DJ, Blomhoff A, Watson PF, Weetman AP, Kemp EH. A single-nucleotide polymorphism in the gene encoding lymphoid protein tyrosine phosphatase (PTPN22) confers susceptibility to generalised vitiligo. Genes Immun 2005; 6:584-7.
124. LaBerge GS, Bennett DC, Fain PR, Spritz RA. PTPN22 is genetically associated with risk of generalized vitiligo, but CTLA4 is not. J Investig Dermatol 2008; 128:1757-62.
125. Gourh P, Tan FK, Assassi S, Ahn CW, McNearney TA, Fischbach M, Arnett FC, Mayes MD. Association of the PTPN22 R620W polymorphism with anti-topoisomerase I- and anticentromere antibody-positive systemic sclerosis. Arthritis Rheum 2006; 54:3945-53.
126. Betz RC, Konig K, Flaquer A et al. The R620W polymorphism in PTPN22 confers general susceptibility for the development of alopecia areata. Br J Dermatol 2008; 158:389-91.
127. Huffmeier U, Reis A, Steffens M et al. Male restricted genetic association of variant R620W in PTPN22 with psoriatic arthritis. J Investig Dermatol 2006; 126:932-5.
128. Butt C, Peddle L, Greenwood C, Hamilton S, Gladman D, Rahman P. Association of functional variants of PTPN22 and tp53 in psoriatic arthritis: a case-control study. Arthritis Res Ther 2006; 8:R27.
129. Jagiello P, Aries P, Arning L, Wagenleiter SE, Csernok E, Hellmich B, Gross WL, Epplen JT. The PTPN22 620W allele is a risk factor for Wegener's granulomatosis. Arthritis Rheum 2005; 52:4039-43.
130. Rueda B, Nunez C, Orozco G, Lopez-Nevot MA, de la Concha EG, Martin J, Urcelay E. C1858T functional variant of PTPN22 gene is not associated with celiac disease genetic predisposition. Hum Immunol 2005; 66:848-52.
131. Zhernakova A, Stahl EA, Trynka G et al. Meta-analysis of genome-wide association studies in celiac disease and rheumatoid arthritis identifies fourteen non-HLA shared loci. PLoS Genet 2011; 7:e1002004.
132. Barrett JC, Hansoul S, Nicolae DL et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 2008; 40:955-62.
133. Baranathan V, Stanford MR, Vaughan RW et al. The association of the PTPN22 620W polymorphism with Behcet's disease. Ann Rheum Dis 2007; 66:1531-3.
134. Diaz-Gallo LM, Espino-Paisan L, Fransen K et al. Differential association of two PTPN22 coding variants with Crohn's disease and ulcerative colitis. Inflamm Bowel Dis 2011; 17:2287-94.
135. + T cell activation in children with type 1 diabetes carrying the PTPN22/Lyp 620Trp variant. J Autoimmun 2008; 31:13-21.
136. Rieck M, Arechiga A, Onengut-Gumuscu S, Greenbaum C, Concannon P, Buckner JH. Genetic variation in PTPN22 corresponds to altered function of T and B lymphocytes. J Immunol 2007; 179:4704-10.
137. Zikherman J, Hermiston M, Steiner D, Hasegawa K, Chan A, Weiss A. PTPN22 deficiency cooperates with the CD45 E613R allele to break tolerance on a non-autoimmune background. J Immunol 2009; 182:4093-106.
138. Zhang J, Zahir N, Jiang Q et al. The autoimmune disease-associated PTPN22 variant promotes calpain-mediated Lyp/Pep degradation associated with lymphocyte and dendritic cell hyperresponsiveness. Nat Genet 2011; 43:902-7.
139. Yang Q, Co D, Sommercorn J, Tonks NK. Cloning and expression of PTP-PEST. A novel, human, nontransmembrane protein tyrosine phosphatase. J Biol Chem 1993; 268:17650.
140. Davidson D, Cloutier JF, Gregorieff A, Veillette A. Inhibitory tyrosine protein kinase p50csk is associated with protein-tyrosine phosphatase PTP-PEST in hemopoietic and non-hemopoietic cells. J Biol Chem 1997; 272:23455-62.
141. Charest A, Wagner J, Shen SH, Tremblay ML. Murine protein tyrosine phosphatase-PEST, a stable cytosolic protein tyrosine phosphatase. Biochem J 1995; 308(Pt 2):425-32.
142. Garton AJ, Flint AJ, Tonks NK. Identification of p130(cas) as a substrate for the cytosolic protein tyrosine phosphatase PTP-PEST. Mol Cell Biol 1996; 16:6408-18.
143. Shen Y, Lyons P, Cooley M, Davidson D, Veillette A, Salgia R, Griffin JD, Schaller MD. The noncatalytic domain of protein-tyrosine phosphatase-PEST targets paxillin for dephosphorylation in vivo. J Biol Chem 2000; 275:1405-13.
144. Arimura Y, Vang T, Tautz L, Williams S, Mustelin T. TCR-induced downregulation of protein tyrosine phosphatase PEST augments secondary T cell responses. Mol Immunol 2008; 45:3074-84.
145. Davidson D, Veillette A. PTP-PEST, a scaffold protein tyrosine phosphatase, negatively regulates lymphocyte activation by targeting a unique set of substrates. EMBO J 2001; 20:3414-26.
146. Badour K, Zhang J, Shi F, Leng Y, Collins M, Siminovitch KA. Fyn and PTP-PEST-mediated regulation of Wiskott-Aldrich syndrome protein (WASp) tyrosine phosphorylation is required for coupling T cell antigen receptor engagement to WASp effector function and T cell activation. J Exp Med 2004; 199:99-112.
147. Sirois J, Cote JF, Charest A, Uetani N, Bourdeau A, Duncan SA, Daniels E, Tremblay ML. Essential function of PTP-PEST during mouse embryonic vascularization, mesenchyme formation, neurogenesis and early liver development. Mech Dev 2006; 123:869-80.
148. Davidson D, Shi X, Zhong MC, Rhee I, Veillette A. The phosphatase PTP-PEST promotes secondary T cell responses by dephosphorylating the protein tyrosine kinase Pyk2. Immunity 2010; 33:167-80.
149. Yi TL, Cleveland JL, Ihle JN. Protein tyrosine phosphatase containing SH2 domains: characterization, preferential expression in hematopoietic cells, and localization to human chromosome 12p12-p13. Mol Cell Biol 1992; 12:836-46.
150. Plutzky J, Neel BG, Rosenberg RD. Isolation of a src homology 2-containing tyrosine phosphatase. Proc Natl Acad Sci U S A 1992; 89:1123-7.
151. Walton KM, Martell KJ, Kwak SP, Dixon JE, Largent BL. A novel receptor-type protein tyrosine phosphatase is expressed during neurogenesis in the olfactory neuroepithelium. Neuron 1993; 11:387-400.
152. Banville D, Stocco R, Shen SH. Human protein tyrosine phosphatase 1C (PTPN6) gene structure: alternate promoter usage and exon skipping generate multiple transcripts. Genomics 1995; 27:165-73.
153. Jin YJ, Yu CL, Burakoff SJ. Human 70-kDa SHP-1L differs from 68-kDa SHP-1 in its C-terminal structure and catalytic activity. J Biol Chem 1999; 274:28301-7.
154. Feng GS, Hui CC, Pawson T. SH2-containing phosphotyrosine phosphatase as a target of protein-tyrosine kinases. Science (New York, NY) 1993; 259:1607-11.
155. Freeman RM Jr, Plutzky J, Neel BG. Identification of a human src homology 2-containing protein-tyrosine-phosphatase: a putative homolog of Drosophila corkscrew. Proc Natl Acad Sci U S A 1992; 89:11239-43.
156. Hof P, Pluskey S, Dhe-Paganon S, Eck MJ, Shoelson SE. Crystal structure of the tyrosine phosphatase SHP-2. Cell 1998; 92:441-50.
157. Pei D, Wang J, Walsh CT. Differential functions of the two Src homology 2 domains in protein tyrosine phosphatase SH-PTP1. Proc Natl Acad Sci U S A 1996; 93:1141-5.
158. Dechert U, Adam M, Harder KW, Clark-Lewis I, Jirik F. Characterization of protein tyrosine phosphatase SH-PTP2. Study of phosphopeptide substrates and possible regulatory role of SH2 domains. J Biol Chem 1994; 269:5602-11.
159. Pei D, Lorenz U, Klingmuller U, Neel BG, Walsh CT. Intramolecular regulation of protein tyrosine phosphatase SH-PTP1: a new function for Src homology 2 domains. Biochemistry 1994; 33:15483-93.
160. Townley R, Shen SH, Banville D, Ramachandran C. Inhibition of the activity of protein tyrosine phosphate 1C by its SH2 domains. Biochemistry 1993; 32:13414-8.
161. Zhao Z, Bouchard P, Diltz CD, Shen SH, Fischer EH. Purification and characterization of a protein tyrosine phosphatase containing SH2 domains. J Biol Chem 1993; 268:2816-20.
162. Bennett AM, Tang TL, Sugimoto S, Walsh CT, Neel BG. Protein-tyrosine-phosphatase SHPTP2 couples platelet-derived growth factor receptor β to Ras. Proc Natl Acad Sci U S A 1994; 91:7335-9.
163. Lorenz U, Ravichandran KS, Pei D, Walsh CT, Burakoff SJ, Neel BG. Lck-dependent tyrosyl phosphorylation of the phosphotyrosine phosphatase SH-PTP1 in murine T cells. Mol Cell Biol 1994; 14:1824-34.
164. Uchida T, Matozaki T, Noguchi T et al. Insulin stimulates the phosphorylation of Tyr538 and the catalytic activity of PTP1C, a protein tyrosine phosphatase with Src homology-2 domains. J Biol Chem 1994; 269:12220-8.
165. Yoshida K, Kharbanda S, Kufe D. Functional interaction between SHPTP1 and the Lyn tyrosine kinase in the apoptotic response to DNA damage. J Biol Chem 1999; 274:34663-8.
166. Zhang T, Ma J, Cao X. Grb2 regulates Stat3 activation negatively in epidermal growth factor signalling. Biochem J 2003; 376(Pt 2):457-64.
167. Sankarshanan M, Ma Z, Iype T, Lorenz U. Identification of a novel lipid raft-targeting motif in Src homology 2-containing phosphatase 1. J Immunol 2007; 179:483-90.
168. Poole AW, Jones ML. A SHPing tale: perspectives on the regulation of SHP-1 and SHP-2 tyrosine phosphatases by the C-terminal tail. Cell Signal 2005; 17:1323-32.
169. Tsui FW, Martin A, Wang J, Tsui HW. Investigations into the regulation and function of the SH2 domain-containing protein-tyrosine phosphatase, SHP-1. Immunol Res 2006; 35:127-36.
170. Lorenz U. SHP-1 and SHP-2 in T cells: two phosphatases functioning at many levels. Immunol Rev 2009; 228:342-59.
171. Pao LI, Badour K, Siminovitch KA, Neel BG. Nonreceptor protein-tyrosine phosphatases in immune cell signaling. Annu Rev Immunol 2007; 25:473-523.
172. Johnson KG, LeRoy FG, Borysiewicz LK, Matthews RJ. TCR signaling thresholds regulating T cell development and activation are dependent upon SHP-1. J Immunol 1999; 162:3802-13.
173. Carter JD, Neel BG, Lorenz U. The tyrosine phosphatase SHP-1 influences thymocyte selection by setting TCR signaling thresholds. Int Immunol 1999; 11:1999-2014.
174. Shultz LD, Rajan TV, Greiner DL. Severe defects in immunity and hematopoiesis caused by SHP-1 protein-tyrosine-phosphatase deficiency. Trends Biotechnol 1997; 15:302-7.
175. Zhang J, Somani AK, Siminovitch KA. Roles of the SHP-1 tyrosine phosphatase in the negative regulation of cell signalling. Semin Immunol 2000; 12:361-78.
176. Plas DR, Johnson R, Pingel JT, Matthews RJ, Dalton M, Roy G, Chan AC, Thomas ML. Direct regulation of ZAP-70 by SHP-1 in T cell antigen receptor signaling. Science (New York, NY) 1996; 272:1173-6.
177. Stefanova I, Hemmer B, Vergelli M, Martin R, Biddison WE, Germain RN. TCR ligand discrimination is enforced by competing ERK positive and SHP-1 negative feedback pathways. Nat Immunol 2003; 4:248-54.
178. Zhang J, Somani AK, Yuen D, Yang Y, Love PE, Siminovitch KA. Involvement of the SHP-1 tyrosine phosphatase in regulation of T cell selection. J Immunol 1999; 163:3012-21.
179. Plas DR, Williams CB, Kersh GJ et al. Cutting edge: the tyrosine phosphatase SHP-1 regulates thymocyte positive selection. J Immunol 1999; 162:5680-4.
180. Fowler CC, Pao LI, Blattman JN, Greenberg PD. SHP-1 in T cells limits the production of CD8 effector cells without impacting the formation of long-lived central memory cells. J Immunol 2010; 185:3256-67.
181. Chen Z, Chen L, Qiao SW, Nagaishi T, Blumberg RS. Carcinoembryonic antigen-related cell adhesion molecule 1 inhibits proximal TCR signaling by targeting ZAP-70. J Immunol 2008; 180:6085-93.
182. + T lymphocyte activation. J Immunol 2008; 180:6827-35.
183. Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol 2004; 173:945-54.
184. Sathish JG, Walters J, Luo JC et al. CD22 is a functional ligand for SH2 domain-containing protein-tyrosine phosphatase-1 in primary T cells. J Biol Chem 2004; 279:47783-91.
185. Perez-Villar JJ, Whitney GS, Bowen MA, Hewgill DH, Aruffo AA, Kanner SB. CD5 negatively regulates the T-cell antigen receptor signal transduction pathway: involvement of SH2-containing phosphotyrosine phosphatase SHP-1. Mol Cell Biol 1999; 19:2903-12.
186. Watanabe N, Gavrieli M, Sedy JR et al. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol 2003; 4:670-9.
187. Gavrieli M, Watanabe N, Loftin SK, Murphy TL, Murphy KM. Characterization of phosphotyrosine binding motifs in the cytoplasmic domain of B and T lymphocyte attenuator required for association with protein tyrosine phosphatases SHP-1 and SHP-2. Biochem Biophys Res Commun 2003; 312:1236-43.
188. Migone TS, Cacalano NA, Taylor N, Yi T, Waldmann TA, Johnston JA. Recruitment of SH2-containing protein tyrosine phosphatase SHP-1 to the interleukin 2 receptor; loss of SHP-1 expression in human T-lymphotropic virus type I-transformed T cells. Proc Natl Acad Sci U S A 1998; 95:3845-50.
189. Tsui HW, Siminovitch KA, de Souza L, Tsui FW. Motheaten and viable motheaten mice have mutations in the haematopoietic cell phosphatase gene. Nat Genet 1993; 4:124-9.
190. Eriksen KW, Woetmann A, Skov L et al. Deficient SOCS3 and SHP-1 expression in psoriatic T cells. J Investig Dermatol 2010; 130:1590-7.
191. Deng C, Minguela A, Hussain RZ, Lovett-Racke AE, Radu C, Ward ES, Racke MK. Expression of the tyrosine phosphatase SRC homology 2 domain-containing protein tyrosine phosphatase 1 determines T cell activation threshold and severity of experimental autoimmune encephalomyelitis. J Immunol 2002; 168:4511-8.
192. Saxton TM, Henkemeyer M, Gasca S, Shen R, Rossi DJ, Shalaby F, Feng GS, Pawson T. Abnormal mesoderm patterning in mouse embryos mutant for the SH2 tyrosine phosphatase Shp-2. EMBO J 1997; 16:2352-64.
193. Qu CK, Nguyen S, Chen J, Feng GS. Requirement of Shp-2 tyrosine phosphatase in lymphoid and hematopoietic cell development. Blood 2001; 97:911-4.
194. Nguyen TV, Ke Y, Zhang EE, Feng GS. Conditional deletion of Shp2 tyrosine phosphatase in thymocytes suppresses both pre-TCR and TCR signals. J Immunol 2006; 177:5990-6.
195. Kwon J, Qu CK, Maeng JS, Falahati R, Lee C, Williams MS. Receptor-stimulated oxidation of SHP-2 promotes T-cell adhesion through SLP-76-ADAP. EMBO J 2005; 24:2331-41.
196. Gu H, Pratt JC, Burakoff SJ, Neel BG. Cloning of p97/Gab2, the major SHP2-binding protein in hematopoietic cells, reveals a novel pathway for cytokine-induced gene activation. Mol Cell 1998; 2:729-40.
197. Arnaud M, Crouin C, Deon C, Loyaux D, Bertoglio J. Phosphorylation of Grb2-associated binder 2 on serine 623 by ERK MAPK regulates its association with the phosphatase SHP-2 and decreases STAT5 activation. J Immunol 2004; 173:3962-71.
198. Arnaud M, Mzali R, Gesbert F et al. Interaction of the tyrosine phosphatase SHP-2 with Gab2 regulates Rho-dependent activation of the c-fos serum response element by interleukin-2. Biochem J 2004; 382(Pt 2):545-56.
199. Newman DK, Hamilton C, Newman PJ. Inhibition of antigen-receptor signaling by Platelet Endothelial Cell Adhesion Molecule-1 (CD31) requires functional ITIMs, SHP-2, and p56(lck). Blood 2001; 97:2351-7.
200. Genome-wide association study of 14, 000 cases of seven common diseases and 3, 000 shared controls. Nature 2007; 447:661-78.
201. Mosinger B Jr, Tillmann U, Westphal H, Tremblay ML. Cloning and characterization of a mouse cDNA encoding a cytoplasmic protein-tyrosine-phosphatase. Proc Natl Acad Sci U S A 1992; 89:499-503.
202. Tillmann U, Wagner J, Boerboom D, Westphal H, Tremblay ML. Nuclear localization and cell cycle regulation of a murine protein tyrosine phosphatase. Mol Cell Biol 1994; 14:3030-40.
203. Gjorloff-Wingren A, Saxena M, Han S et al. Subcellular localization of intracellular protein tyrosine phosphatases in T cells. Eur J Immunol 2000; 30:2412-21.
204. Simoncic PD, Lee-Loy A, Barber DL, Tremblay ML, McGlade CJ. The T cell protein tyrosine phosphatase is a negative regulator of Janus family kinases 1 and 3. Curr Biol 2002; 12:446-53.
205. Zhu W, Mustelin T, David M. Arginine methylation of STAT1 regulates its dephosphorylation by T cell protein tyrosine phosphatase. J Biol Chem 2002; 277:35787-90.
206. You-Ten KE, Muise ES, Itie A, Michaliszyn E, Wagner J, Jothy S, Lapp WS, Tremblay ML. Impaired bone marrow microenvironment and immune function in T cell protein tyrosine phosphatase-deficient mice. J Exp Med 1997; 186:683-93.
207. Dupuis M, De Jesus Ibarra-Sanchez M, Tremblay ML, Duplay P. Gr-1+ myeloid cells lacking T cell protein tyrosine phosphatase inhibit lymphocyte proliferation by an IFN-γ- and nitric oxide-dependent mechanism. J Immunol 2003; 171:726-32.
208. Wiede F, Shields BJ, Chew SH et al. T cell protein tyrosine phosphatase attenuates T cell signaling to maintain tolerance in mice. J Clin Investig 2011; 121:4758-74.
209. Parkes M, Barrett JC, Prescott NJ et al. Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. Nat Genet 2007; 39:830-2.
210. Franke A, Balschun T, Karlsen TH et al. Replication of signals from recent studies of Crohn's disease identifies previously unknown disease loci for ulcerative colitis. Nat Genet 2008; 40:713-5.
211. Todd JA, Walker NM, Cooper JD et al. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet 2007; 39:857-64.
212. + T cells. Genes Immun 2011; 12:116-25.
213. Itoh F, Ikuta S, Hinoda Y et al. Expression and chromosomal assignment of PTPH1 gene encoding a cytosolic protein tyrosine phosphatase homologous to cytoskeletal-associated proteins. Int J Cancer 1993; 55:947-51.
214. Sozio MS, Mathis MA, Young JA et al. PTPH1 is a predominant protein-tyrosine phosphatase capable of interacting with and dephosphorylating the T cell receptor zeta subunit. J Biol Chem 2004; 279:7760-9.
215. Han S, Williams S, Mustelin T. Cytoskeletal protein tyrosine phosphatase PTPH1 reduces T cell antigen receptor signaling. Eur J Immunol 2000; 30:1318-25.
216. Zhang SH, Liu J, Kobayashi R, Tonks NK. Identification of the cell cycle regulator VCP (p97/CDC48) as a substrate of the band 4.1-related protein-tyrosine phosphatase PTPH1. J Biol Chem 1999; 274:17806-12.
217. Zheng Y, Schlondorff J, Blobel CP. Evidence for regulation of the tumor necrosis factor alpha-convertase (TACE) by protein-tyrosine phosphatase PTPH1. J Biol Chem 2002; 277:42463-70.
218. Hou SW, Zhi HY, Pohl N, Loesch M, Qi XM, Li RS, Basir Z, Chen G. PTPH1 dephosphorylates and cooperates with p38γ MAPK to increase ras oncogenesis through PDZ-mediated interaction. Cancer Res 2010; 70:2901-10.
219. Gu MX, York JD, Warshawsky I, Majerus PW. Identification, cloning, and expression of a cytosolic megakaryocyte protein-tyrosine-phosphatase with sequence homology to cytoskeletal protein 4.1. Proc Natl Acad Sci U S A 1991; 88:5867-71.
220. Bauler TJ, Hendriks WJ, King PD. The FERM and PDZ domain-containing protein tyrosine phosphatases, PTPN4 and PTPN3, are both dispensable for T cell receptor signal transduction. PLoS ONE 2008; 3:e4014.
221. Young JA, Becker AM, Medeiros JJ et al. The protein tyrosine phosphatase PTPN4/PTP-MEG1, an enzyme capable of dephosphorylating the TCR ITAMs and regulating NF-κB, is dispensable for T cell development and/or T cell effector functions. Mol Immunol 2008; 45:3756-66.
222. Abaan OD, Toretsky JA. PTPL1: a large phosphatase with a split personality. Cancer Metastasis Rev 2008; 27:205-14.
223. Ivanov VN, Ronai Z, Hei TK. Opposite roles of FAP-1 and dynamin in the regulation of Fas (CD95) translocation to the cell surface and susceptibility to Fas ligand-mediated apoptosis. J Biol Chem 2006; 281:1840-52.
224. Nakahira M, Tanaka T, Robson BE, Mizgerd JP, Grusby MJ. Regulation of signal transducer and activator of transcription signaling by the tyrosine phosphatase PTP-BL. Immunity 2007; 26:163-76.
225. Bauler TJ, Hughes ED, Arimura Y, Mustelin T, Saunders TL, King PD. Normal TCR signal transduction in mice that lack catalytically active PTPN3 protein tyrosine phosphatase. J Immunol 2007; 178:3680-7.
226. Pilecka I, Patrignani C, Pescini R et al. Protein-tyrosine phosphatase H1 controls growth hormone receptor signaling and systemic growth. J Biol Chem 2007; 282:35405-15.
227. Gu M, Warshawsky I, Majerus PW. Cloning and expression of a cytosolic megakaryocyte protein-tyrosine-phosphatase with sequence homology to retinaldehyde-binding protein and yeast SEC14p. Proc Natl Acad Sci U S A 1992; 89:2980-4.
228. Huynh H, Wang X, Li W et al. Homotypic secretory vesicle fusion induced by the protein tyrosine phosphatase MEG2 depends on polyphosphoinositides in T cells. J Immunol 2003; 171:6661-71.
229. Huynh H, Bottini N, Williams S et al. Control of vesicle fusion by a tyrosine phosphatase. Nat Cell Biol 2004; 6:831-9.
230. Wang X, Huynh H, Gjorloff-Wingren A, Monosov E, Stridsberg M, Fukuda M, Mustelin T. Enlargement of secretory vesicles by protein tyrosine phosphatase PTP-MEG2 in rat basophilic leukemia mast cells and Jurkat T cells. J Immunol 2002; 168:4612-9.
231. Zhao R, Fu X, Li Q, Krantz SB, Zhao ZJ. Specific interaction of protein tyrosine phosphatase-MEG2 with phosphatidylserine. J Biol Chem 2003; 278:22609-14.
232. Wang Y, Vachon E, Zhang J et al. Tyrosine phosphatase MEG2 modulates murine development and platelet and lymphocyte activation through secretory vesicle function. J Exp Med 2005; 202:1587-97.
233. Lang R, Hammer M, Mages J. DUSP meet immunology: dual specificity MAPK phosphatases in control of the inflammatory response. J Immunol 2006; 177:7497-504.
234. Owens DM, Keyse SM. Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases. Oncogene 2007; 26:3203-13.
235. Patterson KI, Brummer T, O'Brien PM, Daly RJ. Dual-specificity phosphatases: critical regulators with diverse cellular targets. Biochem J 2009; 418:475-89.
236. Barr AJ, Knapp S. MAPK-specific tyrosine phosphatases: new targets for drug discovery?Trends Pharmacol Sci 2006; 27:525-30.
237. Pulido R, Zuniga A, Ullrich A. PTP-SL and STEP protein tyrosine phosphatases regulate the activation of the extracellular signal-regulated kinases ERK1 and ERK2 by association through a kinase interaction motif. EMBO J 1998; 17:7337-50.
238. Saxena M, Williams S, Brockdorff J, Gilman J, Mustelin T. Inhibition of T cell signaling by mitogen-activated protein kinase-targeted hematopoietic tyrosine phosphatase (HePTP). J Biol Chem 1999; 274:11693-700.
239. Adachi M, Sekiya M, Isobe M, Kumura Y, Ogita Z, Hinoda Y, Imai K, Yachi A. Molecular cloning and chromosomal mapping of a human protein-tyrosine phosphatase LC-PTP. Biochem Biophys Res Commun 1992; 186:1607-15.
240. Zanke B, Suzuki H, Kishihara K, Mizzen L, Minden M, Pawson A, Mak TW. Cloning and expression of an inducible lymphoid-specific, protein tyrosine phosphatase (HePTPase). Eur J Immunol 1992; 22:235-9.
241. Saxena M, Williams S, Gilman J, Mustelin T. Negative regulation of T cell antigen receptor signal transduction by hematopoietic tyrosine phosphatase (HePTP). J Biol Chem 1998; 273:15340-4.
242. Oh-hora M, Ogata M, Mori Y, Adachi M, Imai K, Kosugi A, Hamaoka T. Direct suppression of TCR-mediated activation of extracellular signal-regulated kinase by leukocyte protein tyrosine phosphatase, a tyrosine-specific phosphatase. J Immunol 1999; 163:1282-8.
243. Gronda M, Arab S, Iafrate B, Suzuki H, Zanke BW. Hematopoietic protein tyrosine phosphatase suppresses extracellular stimulus-regulated kinase activation. Mol Cell Biol 2001; 21:6851-8.
244. Saxena M, Williams S, Tasken K, Mustelin T. Crosstalk between cAMP-dependent kinase and MAP kinase through a protein tyrosine phosphatase. Nat Cell Biol 1999; 1:305-11.
245. Nika K, Hyunh H, Williams S, Paul S, Bottini N, Tasken K, Lombroso PJ, Mustelin T. Haematopoietic protein tyrosine phosphatase (HePTP) phosphorylation by cAMP-dependent protein kinase in T-cells: dynamics and subcellular location. Biochem J 2004; 378(Pt 2):335-42.
246. Mustelin T, Alonso A, Bottini N et al. Protein tyrosine phosphatases in T cell physiology. Mol Immunol 2004; 41:687-700.
247. Nika K, Charvet C, Williams S et al. Lipid raft targeting of hematopoietic protein tyrosine phosphatase by protein kinase Cθ-mediated phosphorylation. Mol Cell Biol 2006; 26:1806-16.
248. Wu JJ, Bennett AM. Essential role for mitogen-activated protein (MAP) kinase phosphatase-1 in stress-responsive MAP kinase and cell survival signaling. J Biol Chem 2005; 280:16461-6.
249. Liu Y, Shepherd EG, Nelin LD. MAPK phosphatases - regulating the immune response. Nat Rev 2007; 7:202-12.
250. Zhang Y, Reynolds JM, Chang SH, Martin-Orozco N, Chung Y, Nurieva RI, Dong C. MKP-1 is necessary for T cell activation and function. J Biol Chem 2009; 284:30815-24.
251. Rohan PJ, Davis P, Moskaluk CA, Kearns M, Krutzsch H, Siebenlist U, Kelly K. PAC-1: a mitogen-induced nuclear protein tyrosine phosphatase. Science (New York, NY) 1993; 259:1763-6.
252. Grumont RJ, Rasko JE, Strasser A, Gerondakis S. Activation of the mitogen-activated protein kinase pathway induces transcription of the PAC-1 phosphatase gene. Mol Cell Biol 1996; 16:2913-21.
253. Jeffrey KL, Brummer T, Rolph MS et al. Positive regulation of immune cell function and inflammatory responses by phosphatase PAC-1. Nat Immunol 2006; 7:274-83.
254. Ward Y, Gupta S, Jensen P, Wartmann M, Davis RJ, Kelly K. Control of MAP kinase activation by the mitogen-induced threonine/tyrosine phosphatase PAC1. Nature 1994; 367:651-4.
255. Chu Y, Solski PA, Khosravi-Far R, Der CJ, Kelly K. The mitogen-activated protein kinase phosphatases PAC1, MKP-1, and MKP-2 have unique substrate specificities and reduced activity in vivo toward the ERK2 sevenmaker mutation. J Biol Chem 1996; 271:6497-501.
256. + T-cell proliferation without impeding T-cell development. Eur J Immunol 2012; 42:476-88.
257. Bettini ML, Kersh GJ. MAP kinase phosphatase activity sets the threshold for thymocyte positive selection. Proc Natl Acad Sci U S A 2007; 104:16257-62.
258. + T cells regulates TCR activation and experimental colitis in mice. J Clin Investig 2010; 120:570-81.
259. Zhang Y, Blattman JN, Kennedy NJ et al. Regulation of innate and adaptive immune responses by MAP kinase phosphatase 5. Nature 2004; 430:793-7.
260. Musikacharoen T, Bandow K, Kakimoto K, Kusuyama J, Onishi T, Yoshikai Y, Matsuguchi T. Functional involvement of dual specificity phosphatase 16 (DUSP16), a c-Jun N-terminal kinase-specific phosphatase, in the regulation of T helper cell differentiation. J Biol Chem 2011; 286:24896-905.
261. Masuda K, Shima H, Watanabe M, Kikuchi K. MKP-7, a novel mitogen-activated protein kinase phosphatase, functions as a shuttle protein. J Biol Chem 2001; 276:39002-11.
262. Alonso A, Saxena M, Williams S, Mustelin T. Inhibitory role for dual specificity phosphatase VHR in T cell antigen receptor and CD28-induced Erk and Jnk activation. J Biol Chem 2001; 276:4766-71.
263. Alonso A, Rahmouni S, Williams S et al. Tyrosine phosphorylation of VHR phosphatase by ZAP-70. Nat Immunol 2003; 4:44-8.
264. Rahmouni S, Cerignoli F, Alonso A et al. Loss of the VHR dual-specific phosphatase causes cell-cycle arrest and senescence. Nat Cell Biol 2006; 8:524-31.
265. Hoyt R, Zhu W, Cerignoli F, Alonso A, Mustelin T, David M. Cutting edge: selective tyrosine dephosphorylation of interferon-activated nuclear STAT5 by the VHR phosphatase. J Immunol 2007; 179:3402-6.
266. Marti F, Krause A, Post NH, Lyddane C, Dupont B, Sadelain M, King PD. Negative-feedback regulation of CD28 costimulation by a novel mitogen-activated protein kinase phosphatase, MKP6. J Immunol 2001; 166:197-206.
267. Alonso A, Merlo JJ, Na S et al. Inhibition of T cell antigen receptor signaling by VHR-related MKPX (VHX), a new dual specificity phosphatase related to VH1 related (VHR). J Biol Chem 2002; 277:5524-8.
268. Maehama T, Taylor GS, Dixon JE. PTEN and myotubularin: novel phosphoinositide phosphatases. Annu Rev Biochem 2001; 70:247-79.
269. Suzuki A, Yamaguchi MT, Ohteki T et al. T cell-specific loss of Pten leads to defects in central and peripheral tolerance. Immunity 2001; 14:523-34.
270. Seminario MC, Wange RL. Lipid phosphatases in the regulation of T cell activation: living up to their PTEN-tial. Immunol Rev 2003; 192:80-97.
271. Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP. Pten is essential for embryonic development and tumour suppression. Nat Genet 1998; 19:348-55.
272. +/- mice. Science (New York, NY) 1999; 285:2122-5.
273. Souza AC, Azoubel S, Queiroz KC, Peppelenbosch MP, Ferreira CV. From immune response to cancer: a spot on the low molecular weight protein tyrosine phosphatase. Cell Mol Life Sci 2009; 66:1140-53.
274. Bottini N, Bottini E, Gloria-Bottini F, Mustelin T. Low-molecular-weight protein tyrosine phosphatase and human disease: in search of biochemical mechanisms. Arch Immunol Ther Exp (Warsz) 2002; 50:95-104.
275. Chiarugi P, Cirri P, Taddei ML et al. Insight into the role of low molecular weight phosphotyrosine phosphatase (LMW-PTP) on platelet-derived growth factor receptor (PDGF-r) signaling. LMW-PTP controls PDGF-r kinase activity through TYR-857 dephosphorylation. J Biol Chem 2002; 277:37331-8.
276. Spencer N, Hopkinson DA, Harris H. Quantitative differences and gene dosage in the human red cell acid phosphatase polymorphism. Nature 1964; 201:299-300.
277. Dissing J. Immunochemical characterization of human red cell acid phosphatase isozymes. Biochem Genet 1987; 25:901-18.
278. r phosphotyrosine protein phosphatase. FEBS Lett 1995; 372:49-53.
279. Park EK, Warner N, Mood K, Pawson T, Daar IO. Low-molecular-weight protein tyrosine phosphatase is a positive component of the fibroblast growth factor receptor signaling pathway. Mol Cell Biol 2002; 22:3404-14.
280. Pandey SK, Yu XX, Watts LM et al. Reduction of low molecular weight protein-tyrosine phosphatase expression improves hyperglycemia and insulin sensitivity in obese mice. J Biol Chem 2007; 282:14291-9.
281. Kikawa KD, Vidale DR, Van Etten RL, Kinch MS. Regulation of the EphA2 kinase by the low molecular weight tyrosine phosphatase induces transformation. J Biol Chem 2002; 277:39274-9.
282. Bottini N, Stefanini L, Williams S, Alonso A, Jascur T, Abraham RT, Couture C, Mustelin T. Activation of ZAP-70 through specific dephosphorylation at the inhibitory Tyr-292 by the low molecular weight phosphotyrosine phosphatase (LMPTP). J Biol Chem 2002; 277:24220-4.
283. Giannoni E, Chiarugi P, Cozzi G et al. Lymphocyte function-associated antigen-1-mediated T cell adhesion is impaired by low molecular weight phosphotyrosine phosphatase-dependent inhibition of FAK activity. J Biol Chem 2003; 278:36763-76.
284. Tailor P, Gilman J, Williams S, Couture C, Mustelin T. Regulation of the low molecular weight phosphotyrosine phosphatase by phosphorylation at tyrosines 131 and 132. J Biol Chem 1997; 272:5371-4.
285. Bucciantini M, Chiarugi P, Cirri P, Taddei L, Stefani M, Raugei G, Nordlund P, Ramponi G. The low Mr phosphotyrosine protein phosphatase behaves differently when phosphorylated at Tyr131 or Tyr132 by Src kinase. FEBS Lett 1999; 456:73-8.
286. Giannoni E, Raugei G, Chiarugi P, Ramponi G. A novel redox-based switch: LMW-PTP oxidation enhances Grb2 binding and leads to ERK activation. Biochem Biophys Res Commun 2006; 348:367-73.
287. Bottini N, Gloria-Bottini F, Lucarini N, Ronchetti PG, Fontana L. Inflammatory bowel disease: are there gender differences in the genetics of signal transduction? A preliminary study of cytosolic low molecular weight protein tyrosine phosphatase. Dis Markers 2000; 16:163-6.
288. Gloria-Bottini F, Bottini N, Renzetti G, Bottini E. ACP1 and Th class of immunological disease: evidence of interaction with gender. Int Arch Allergy Immunol 2007; 143:170-6.
289. Bottini N, Meloni GF, Lucarelli P, Amante A, Saccucci P, Gloria-Bottini F, Bottini E. Risk of type 1 diabetes in childhood and maternal age at delivery, interaction with ACP1 and sex. Diabetes Metab Res Rev 2005; 21:353-8.
290. Meloni G, Bottini N, Borgiani P, Lucarelli P, Meloni T, Bottini E. Association of the ACP1 genotype with metabolic parameters upon initial diagnosis of type 1 diabetes. Med Sci Monit 2003; 9:CR105-8.